UA115257C2 - Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін - Google Patents

Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін

Info

Publication number
UA115257C2
UA115257C2 UAA201507042A UAA201507042A UA115257C2 UA 115257 C2 UA115257 C2 UA 115257C2 UA A201507042 A UAA201507042 A UA A201507042A UA A201507042 A UAA201507042 A UA A201507042A UA 115257 C2 UA115257 C2 UA 115257C2
Authority
UA
Ukraine
Prior art keywords
candesartan cilexetil
composition
pharmaceutical composition
amlodipine
composition containing
Prior art date
Application number
UAA201507042A
Other languages
English (en)
Inventor
Агнешка Цеплуха
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115257(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of UA115257C2 publication Critical patent/UA115257C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується комбінованої фармацевтичної композиції, у формі твердої суміші, що складається з гранульованого матеріалу, що містить кандесартану цилексетил, поліетиленгліколь та інші допоміжні засоби, де вагове співвідношення кандесартану цилексетилу та поліетиленгліколю становить 4,8:1, та позагранулярної фази, що являє собою порошкову суміш, що містить амлодипін або його фармацевтично прийнятну сіль та допоміжні засоби, способу одержання такої композиції та стандартної лікарської форми, що містить таку композицію.
UAA201507042A 2012-12-21 2013-12-19 Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін UA115257C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL402191A PL236001B1 (pl) 2012-12-21 2012-12-21 Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
PCT/IB2013/061138 WO2014097209A1 (en) 2012-12-21 2013-12-19 A pharmaceutical composition containing candesartan cilexetil and amlodipine

Publications (1)

Publication Number Publication Date
UA115257C2 true UA115257C2 (uk) 2017-10-10

Family

ID=50030379

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201507042A UA115257C2 (uk) 2012-12-21 2013-12-19 Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін

Country Status (19)

Country Link
EP (1) EP2934488B1 (uk)
AU (1) AU2013365715B2 (uk)
BR (1) BR112015014875A2 (uk)
EA (1) EA030704B1 (uk)
ES (1) ES2706067T3 (uk)
HK (1) HK1213808A1 (uk)
HR (1) HRP20190049T1 (uk)
HU (1) HUE042194T2 (uk)
MX (1) MX2015008032A (uk)
MY (1) MY185947A (uk)
PH (1) PH12015501301B1 (uk)
PL (2) PL236001B1 (uk)
PT (1) PT2934488T (uk)
RS (1) RS58214B1 (uk)
SG (1) SG11201504473XA (uk)
TR (1) TR201900350T4 (uk)
UA (1) UA115257C2 (uk)
WO (1) WO2014097209A1 (uk)
ZA (1) ZA201505192B (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3236950B1 (en) * 2014-12-24 2022-11-23 KRKA, d.d., Novo mesto Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof
CN104721159A (zh) * 2015-03-24 2015-06-24 浙江康乐药业股份有限公司 一种苯磺酸氨氯地平片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3219309A1 (en) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
US10350171B2 (en) * 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP4374855A1 (en) * 2022-11-22 2024-05-29 KRKA, D.D., Novo Mesto Pharmaceutical dosage form of candesartan and indapamide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (uk) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
PL189666B1 (pl) 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
WO2004075825A2 (en) 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Dosage forms of amlodipine and processes for their preparation
WO2008065097A2 (en) 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
JP5139515B2 (ja) 2007-04-25 2013-02-06 テバ ファーマシューティカル インダストリーズ リミティド 医薬賦形剤複合体
EP2050440A1 (en) 2007-10-18 2009-04-22 Krka Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof
EP2106789A1 (en) * 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising candesartan
DK2165702T3 (da) 2008-09-17 2012-03-05 Helm Ag Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering
NZ596395A (en) 2009-04-30 2013-06-28 Takeda Pharmaceutical Stable solid benzimidazole derivative preparation having optimized dissolution property
CN101966181A (zh) * 2010-07-08 2011-02-09 王丽燕 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
CN102743381B (zh) * 2011-04-22 2014-08-27 重庆市力扬医药开发有限公司 一种稳定的坎地沙坦酯氨氯地平药物组合物及其制备方法
CN102764258B (zh) 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种坎地沙坦酯氨氯地平复方片的制备方法
CN102670603B (zh) * 2012-04-29 2017-10-31 浙江华海药业股份有限公司 含有坎地沙坦酯和苯磺酸氨氯地平的口服片剂及其制备方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业(石家庄)有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法

Also Published As

Publication number Publication date
HUE042194T2 (hu) 2019-06-28
RS58214B1 (sr) 2019-03-29
ES2706067T3 (es) 2019-03-27
AU2013365715B2 (en) 2017-10-05
PH12015501301A1 (en) 2015-08-24
MY185947A (en) 2021-06-14
HK1213808A1 (zh) 2016-07-15
BR112015014875A2 (pt) 2017-07-11
EA201591097A1 (ru) 2015-10-30
PL236001B1 (pl) 2020-11-30
EP2934488A1 (en) 2015-10-28
PH12015501301B1 (en) 2015-08-24
PT2934488T (pt) 2019-01-29
TR201900350T4 (tr) 2019-02-21
HRP20190049T1 (hr) 2019-02-22
PL402191A1 (pl) 2014-06-23
AU2013365715A1 (en) 2015-06-18
SG11201504473XA (en) 2015-07-30
EP2934488B1 (en) 2018-10-17
ZA201505192B (en) 2016-07-27
WO2014097209A1 (en) 2014-06-26
PL2934488T3 (pl) 2019-04-30
EA030704B1 (ru) 2018-09-28
MX2015008032A (es) 2015-10-30

Similar Documents

Publication Publication Date Title
PH12015501301A1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
GB2495676A (en) Use of binders for manufacturing storage stable formulations
NZ602442A (en) A fast dissolving pharmaceutical composition
IN2014MN01919A (uk)
IL231170A (en) Nitrate mustard derivative compound, pharmaceutical preparation, use of drug preparation and compound for use as a drug
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
SI2729130T1 (en) Combined formulations of darunavir
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
HRP20180316T1 (hr) Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala
PH12014502619A1 (en) Novel dosage and formulation
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2551266A4 (en) NON-NUCLEOSIDE 2 ', 2-DITHIAZOLE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS
TN2012000363A1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT
HRP20171930T1 (hr) Analozi diazonamida
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof